Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevnar 13

- PMLiVE

Researchers suggest delaying second dose of Pfizer/BioNTech jab to protect more people

Canada-based researchers Skowronski and De Serres say first dose is ‘highly protective’

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

EU flag

Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU

The EU now currently has access to 2.6 billion COVID-19 vaccine doses from a range of companies

- PMLiVE

South African variant reduces antibody levels produced by Pifzer/BioNTech’s COVID-19 vaccine

Researchers noted it is 'unclear' what effect this reduction has on the vaccine's protection against the variant

- PMLiVE

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

Blue Latitude Health

- PMLiVE

US secures a further 100 million doses of Pfizer/BioNTech’s COVID-19 vaccine

US government will pay $1.95bn for additional 100 million doses

- PMLiVE

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium

- PMLiVE

Pfizer’s basic instincts

Business model evolution can’t defy strategic gravity

- PMLiVE

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz

EU flag

EU orders another 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine

Pfizer/BioNTech's has an existing agreement with the EU for an initial 300 million doses

- PMLiVE

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Frazier is handing the reins over to current Merck CFO Robert Davis

- PMLiVE

Pfizer aims for $15bn in 2021 COVID-19 vaccine sales

Current estimate is based on already agreed contracts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links